Actinium Pharmaceuticals
ATNM
71 hedge funds and large institutions have $44.8M invested in Actinium Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 16 closing their positions.
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
11% more funds holding
Funds holding: 64 → 71 (+7)
4.25% more ownership
Funds ownership: 18.62% → 22.88% (+4.3%)
0% less capital invested
Capital invested by funds: $45M → $44.8M (-$126K)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
34% less call options, than puts
Call options by funds: $862K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.79M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.28M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.46M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$878K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.19M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 3 |
Jane Street
New York
|
-$967K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$703K |
| 5 |
Goldman Sachs
New York
|
-$674K |
ATNM Hedge Fund Activity: Q2 2023 in Review
71 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2023, worth a combined $44.8M — down 0.28% from $45M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATNM positions and 16 closed out — a net gain of 7 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $9.79M. The largest seller was Millennium Management, exiting entirely with an estimated $2.19M sold.
- 71 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2023, up from 64 in Q1 2023.
- Funds reported $44.8M of Actinium Pharmaceuticals stock for Q2 2023, down 0.28% quarter-over-quarter.
- 23 funds opened new Actinium Pharmaceuticals positions in Q2 2023 and 16 closed out, a net change of +7 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $9.79M added.
- The largest Actinium Pharmaceuticals seller in Q2 2023 was Millennium Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q2 2023.